JP2020530007A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530007A5
JP2020530007A5 JP2020506300A JP2020506300A JP2020530007A5 JP 2020530007 A5 JP2020530007 A5 JP 2020530007A5 JP 2020506300 A JP2020506300 A JP 2020506300A JP 2020506300 A JP2020506300 A JP 2020506300A JP 2020530007 A5 JP2020530007 A5 JP 2020530007A5
Authority
JP
Japan
Prior art keywords
psma
alkyl
drug composition
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020506300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027106 external-priority patent/WO2018191376A2/en
Publication of JP2020530007A publication Critical patent/JP2020530007A/ja
Publication of JP2020530007A5 publication Critical patent/JP2020530007A5/ja
Priority to JP2023061616A priority Critical patent/JP2023093545A/ja
Priority to JP2024199226A priority patent/JP2025028897A/ja
Pending legal-status Critical Current

Links

JP2020506300A 2017-04-11 2018-04-11 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ Pending JP2020530007A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023061616A JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
US62/484,219 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061616A Division JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Publications (2)

Publication Number Publication Date
JP2020530007A JP2020530007A (ja) 2020-10-15
JP2020530007A5 true JP2020530007A5 (https=) 2021-05-20

Family

ID=63792979

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020506300A Pending JP2020530007A (ja) 2017-04-11 2018-04-11 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ
JP2023061616A Pending JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A Pending JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023061616A Pending JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A Pending JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Country Status (10)

Country Link
US (1) US12508271B2 (https=)
EP (1) EP3609544B1 (https=)
JP (3) JP2020530007A (https=)
KR (1) KR102686172B1 (https=)
CN (1) CN111801121B (https=)
AU (1) AU2018250609B2 (https=)
ES (1) ES3021195T3 (https=)
IL (1) IL269969B2 (https=)
SG (1) SG11201909513QA (https=)
WO (1) WO2018191376A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
EP3853213A4 (en) * 2018-09-21 2022-07-06 Endocyte, Inc. Shielding agents and their use
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
US20230330278A1 (en) * 2020-04-29 2023-10-19 Novartis Ag Methods for radiolabelling psma binding ligands and their kits
KR20230002831A (ko) * 2020-04-29 2023-01-05 노파르티스 아게 Psma 결합 리간드의 방사성 표지 방법 및 이의 키트
EP4221763A4 (en) * 2020-10-01 2025-11-12 Univ Cornell METHODS AND COMPOSITIONS FOR INCREASING THE ABSORPTION, INTERNALIZATION AND/OR RETENTION OF SMALL MOLECULE LIGANDS
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US9988407B2 (en) * 2014-08-06 2018-06-05 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
WO2016022809A2 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
AU2015315465B2 (en) 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer

Similar Documents

Publication Publication Date Title
JP2020530007A5 (https=)
CN1318388C (zh) 在光化学疗法中作为光敏剂的5-氨基乙酰丙酸的酯类
TWI385160B (zh) 用於治療增生性疾病的化合物
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
AU2018366219B2 (en) Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
JP2019529518A5 (https=)
JPWO2022177917A5 (https=)
JP2010501584A5 (https=)
AU2017302539B2 (en) Targeted radiotherapy chelates for In Situ Immune Modulated Cancer Vaccination
JP2007509928A5 (https=)
JP5149177B2 (ja) 増殖性疾患の治療のための、チューブリンポリマー化の1,2,3−トリアゾール系抑制剤
JP2005538051A5 (https=)
JP2019011381A5 (https=)
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2016515615A5 (https=)
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
US20190184021A1 (en) Porphyrin Compounds and Compositions Useful for Treating Cancer
JP2006517195A5 (https=)
JPWO2019201283A5 (https=)
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
JP2020532538A5 (https=)
JPWO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
AU2020341213B2 (en) Pharmaceutical composition comprising HDAC inhibitor and anti-PD1 antibody or anti PD-L1 antibody
RU2019104928A (ru) Производное индола, используемое в качестве ингибитора CRTH2
JP5322651B2 (ja) シンチグラフィー法